Waiving Clinical Studies and Accelerating Drug Development for Kinase Inhibitor (KI) Drugs

Explore how Simcyp delivered benefits during multiple stages of the drug cycle, with these information-rich case studies from Certara.

Read now for insights into:

US FDA’s citing of ibrutinib (Imbruvica) example as the best practice for use of PBPK (Simcyp)
Simcyp Simulator’s ability to predict outcomes for a compound with complex, time-dependent,
non-linear PK
Simcyp PBPK simulations relied on for CYP DDI predictions over clinical results
Simcyp’s use in supporting approval of first-in-kind and only treatment for rare pediatric disease
Examples of how >10 clinical pharmacology studies were replaced by PBPK simulations in final drug label
New capabilities for Simcyp; predicting interpatient variability in patients with co-morbidities

Your company email address

Berne Media may store and process my information. For details, see the Privacy Notice.
Citeline (previously Pharma Intelligence UK) may contact me with updates, relevant promotions and information about products. My Information will be used in accordance with the Citeline Privacy Policy, and you withdraw your permission to receive any of our communications at any time.
By clicking submit, you consent to allow Certara to store and process the information submitted to provide you the content requested. They are subject to Certara's Terms and Conditions.

Explore similar content